High-dose (HD) IL-2 was FDA approved for metastatic RCC in 1992 and was able to achieve an objective response rate (ORR) of 14% including 5% of patients achieving a complete response (CR), introducing the feasibility of a cure for a few patients with advanced disease [38,39]. The gene discussed is IL2; the disease is renal cell carcinoma.